Unknown

Dataset Information

0

BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?

ABSTRACT:

SUBMITTER: Markowski MC 

PROVIDER: S-EPMC7655018 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

<i>BRCA1</i> Versus <i>BRCA2</i> and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?

Markowski Mark C MC   Antonarakis Emmanuel S ES  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20200901 32

Similar Datasets

Unknown Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
| S-EPMC7164372 | biostudies-literature
Unknown 5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells.
| S-EPMC12281170 | biostudies-literature
Unknown BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials.
| S-EPMC8580941 | biostudies-literature
Unknown Pathways to Third-Grade Calculation Versus Word-Reading Competence: Are They More Alike or Different?
| S-EPMC4809764 | biostudies-literature
Unknown A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity.
| S-EPMC11238136 | biostudies-literature
Unknown Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.
| S-EPMC12075821 | biostudies-literature
Unknown Development of the PARP inhibitor talazoparib for the treatment of advanced <i>BRCA1</i> and <i>BRCA2</i> mutated breast cancer.
| S-EPMC8478803 | biostudies-literature
Unknown The loss of DNA polymerase epsilon accessory subunits POLE3-POLE4 leads to BRCA1-independent PARP inhibitor sensitivity.
| S-EPMC11229324 | biostudies-literature
Unknown Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in <i>BRCA2</i>-altered Prostate Tumors.
| S-EPMC7956224 | biostudies-literature
Unknown SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer.
| S-EPMC12016936 | biostudies-literature